Biomonitoring: Integration of biological end-points into chemical monitoring

Articles in the same Issue

1. TOPIC 1 MOLECULAR MODE OF ACTION OF NUCLEAR RECEPTORS: FUNDAMENTALS FOR UNDERSTANDING THE ACTION OF ENDOCRINE ACTIVE SUBSTANCES
2. Nuclear receptor superfamily: Principles of signaling
3. Nuclear receptor coregulators
4. Function and mode of action of nuclear receptors: Estrogen, progesterone, and vitamin D
5. Biological function and mode of action of the androgen receptor
6. Genetic dissection of gluco- and mineralocorticoid receptor function in mice
7. Functions of RARs and RXRs in vivo: Genetic dissection of the retinoid signaling pathway
8. Biological function and mode of action of nuclear xenobiotic receptors
9. Molecular mechanisms of cross-talk between growth factors and nuclear receptor signaling
10. Estrogen receptor action through target genes with classical and alternative response elements
11. Nuclear receptor action involved with sex differentiation
12. Human disorders caused by nuclear receptor gene mutations
13. Interactions of exogenous endocrine active substances with nuclear receptors
14. Transcriptional roles of AhR in expression of biological effects induced by endocrine disruptors
15. Nonmammalian nuclear receptors: Evolution and endocrine disruption
16. TOPIC 2 ENVIRONMENTAL FATE AND METABOLISM OF ENDOCRINE ACTIVE SUBSTANCES
17. Analysis of endocrine active substances in food and the environment
18. Naturally produced steroid hormones and their release into the environment
19. Concentration of phytohormones in food and feed and their impact on the human exposure
20. Pharmaceuticals and personal care products - A source of endocrine disruption in the environment?
21. Endocrine active industrial chemicals: Release and occurrence in the environment
22. Release of pesticides into the environment and initial concentrations in soil, water, and plants
23. Role of metabolism in the endocrine-disrupting effects of chemicals in aquatic and terrestrial systems
24. Critical factors in exposure modeling of endocrine active substances
25. Environmental fate and metabolism: Issues and recommendations
26. TOPIC 3 EFFECTS OF ENDOCRINE ACTIVE CHEMICALS IN RODENTS AND HUMANS, AND RISK ASSESSMENTS FOR HUMANS
27. Interactions of xenobiotics with the steroid hormone biosynthesis pathway
28. Organochlorine compounds and breast cancer risk
29. Prevention of ambiguous genitalia by prenatal treatment with dexamethasone in pregnancies at risk for congenital adrenal hyperplasia
30. Male reproductive disorders and the role of endocrine disruption: Advances in understanding and identification of areas for future research
31. Brominated flame retardants and endocrine disruption
32. Toxicity vs. beneficial effects of phytoestrogens
33. Evaluation of thyroid function in neonatal and adult rats: The neglected endocrine mode of action
34. Modification of endocrine active potential by mixtures
35. Experience with new testing guidelines with endocrine-sensitive end-points
36. Critical evaluation of observed adverse effects of endocrine active substances on reproduction and development, the immune system, and the nervous system
37. Significance of experimental studies for assessing adverse effects of endocrine-disrupting chemicals
38. Determination of acceptable exposure levels for humans for endocrine active substances: Use of animal models
39. Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances
40. Endocrine active substances and dose response for individuals and populations
41. Endocrine disruption occurring at doses lower than those predicted by classical chemical toxicity evaluations: The case bisphenol A
42. Environmental estrogens and sperm counts
43. TOPIC 4 EFFECTS OF ENDOCRINE ACTIVE SUBSTANCES IN WILDLIFE SPECIES
44. Historical perspective on endocrine disruption in wildlife
45. Endocrine disruption in invertebrates
46. Endocrine disruption in wild freshwater fish
47. Effects of endocrine disruptors in aquatic mammals
48. Endocrine disruption in marine fish
49. Deformed frogs and environmental retinoids
50. Contaminant-induced endocrine and reproductive alterations in reptiles
51. Review of the effects of endocrine-disrupting chemicals in birds
52. Wildlife as models for the study of how mixtures, low doses, and the embryonic environment modulate the action of endocrine-disrupting chemicals
53. Interactions of endocrine-disrupting chemicals with stress responses in wildlife
54. Effects of endocrine active substances in wildlife species: Genetic, biochemical, and physiological factors in variable susceptibility to endocrine disruptors
55. Development of fish tests for endocrine disruptors
56. Endocrine disruption in wildlife: The future?
57. WORKSHOP 1 EFFECTIVENESS OF QSAR FOR PRESCREENING OF ENDOCRINE DISRUPTOR HAZARD
58. Mechanism-based QSAR approach to the study of the toxicity of endocrine active substances
59. Regulatory application of SAR/QSAR for priority setting of endocrine disruptors: A perspective
60. QSAR prioritization of chemical inventories for endocrine disruptor testing
61. The nature of the ligand-binding pocket of estrogen receptor alpha and beta: The search for subtype-selective ligands and implications for the prediction of estrogenic activity
62. Fragment molecular orbital study of the binding energy of ligands to the estrogen receptor
63. WORKSHOP 2 TOXICOGENOMICS AS A RATIONAL APPROACH TO ENDOCRINE DISRUPTOR RESEARCH
64. Toxicogenomics: Impact on human health
65. Temporal responses to estrogen in the uterus
66. Application of toxicogenomics to the endocrine disruption issue
67. Transcript profiles elicited by developmental exposure to endocrine-mediated toxicants
68. Use of gene expression profiling to understand the transcriptional program associated with estrogen-induced uterine growth
69. WORKSHOP 3 THE NEED FOR ESTABLISHING INTEGRATED MONITORING PROGRAMS
70. Need for establishing integrated programs to monitor endocrine active compounds
71. Search for the evidence of endocrine disruption in the aquatic environment; Lessons to be learned from joint biological and chemical monitoring in the European project COMPREHEND
72. Biomonitoring: Integration of biological end-points into chemical monitoring
73. Identifying the causative agents: The use of combined chemical and biological strategies in monitoring programs
74. Closing the gap between exposure and effects in monitoring studies
75. WORKSHOP 4 SIMPLE, RAPID ASSAY FOR CONVENTIONAL DEFINITIVE TESTINGS OF ENDOCRINE DISRUPTOR HAZARD
76. Simple, rapid assays for conventional definite testing of endocrine disruptor hazard: Summary and recommendations
77. Testing of endocrine active substances using an enhanced OECD test guideline 407: Experiences from studies on flutamide and ethinylestradiol
78. Application of rat medium-term bioassays for detecting carcinogenic and modifying potentials of endocrine active substances
79. Enhanced one-generation reproductive toxicity study in rats for detecting endocrine-disrupting effects of chemicals
80. WORKSHOP 5 PRECAUTIONARY PRINCIPLE/APPROACH AND WEIGHT OF EVIDENCE IN ENDOCRINE DISRUPTOR ISSUES
81. Making decisions in the 21st century: Scientific data, weight of evidence, and the precautionary principle
82. Precautionary principle and endocrine active substances
83. Why epidemiology of endocrine disruptors warrants the precautionary principle
84. General process for the risk assessment of pesticides that interact with or affect the endocrine system
85. Role of the precautionary principle in the EU risk assessment process on industrial chemicals
86. Differing perspectives on the use of scientific evidence and the precautionary principle
87. WORKSHOP 6 RISK MANAGEMENT OPTIONS FOR ENDOCRINE DISRUPTORS IN NATIONAL AND INTERNATIONAL PROGRAMS
88. Risk management options for endocrine disruptors in national and international programs
89. Hormonally active agents and plausible relationships to adverse effects on human health
90. Government view of endocrine disruption in wildlife
91. Risk perception: A chemical industry view of endocrine disruption in wildlife
92. Endocrine active substances and the need to improve environmental protection: An environmentalist's perspective
93. Endocrine disruption and the USFDA's Center for Drug Evaluation and Research
94. Relevant activities for risk management of endocrine disruptors in Japanese government agencies
95. Advancing the testing and assessment of chemical substances for endocrine disruption: OECD activities